Detection of fecal interferon-induced transmembrane protein messenger RNA for colorectal cancer screening

Miyamoto,Chie; Miyamoto,Nobuki; Yamamoto,Hiroyuki; Imai,Kohzoh; Shinomura,Yasuhisa

doi:10.3892/ol.2010.197

Detection of fecal interferon-induced transmembrane protein messenger RNA for colorectal cancer screening

Authors:
- Chie Miyamoto
- Nobuki Miyamoto
- Hiroyuki Yamamoto
- Kohzoh Imai
- Yasuhisa Shinomura
View Affiliations

Affiliations: First Department of Internal Medicine, Sapporo Medical University, Sapporo 060-8543, Japan, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan
Published online on: October 19, 2010 https://doi.org/10.3892/ol.2010.197
Pages: 95-100

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interferon-induced transmembrane protein (IFITM) is reported to be frequently overexpressed in colorectal tumors. This study aimed to determine the usefulness of detecting fecal IFITM messenger RNA (mRNA) by real-time reverse-transcription polymerase chain reaction (RT-PCR) for colorectal cancer (CRC) screening. This pilot study included 21 patients with CRC and 23 healthy controls. Total RNA was isolated from the feces of the patients, and the expression levels of the mRNA of IFITM1, IFITM2 and IFITM3 were measured by real-time RT-PCR to detect CRC. Receiver operating characteristic curves of respective genes were generated, and the area under the curve (AUC), sensitivity and specificity were determined. When the 44 patients were analyzed, the AUCs of fecal IFITM1, IFITM2 and IFITM3 expression analysis were 0.82, 0.80 and 0.65, respectively. The sensitivities were 67% [14/21; 95% confidence interval (CI) 43-85%], 67% (14/21; 95% CI 43-85%) and 71% (15/21; 95% CI 48-89%), respectively; and the specificities were 96% (1/23; 95% CI 78-100%), 96% (1/23; 95% CI 78-100%) and 61% (9/23; 95% CI 39-80%), respectively. When IFITM1 and IFITM2 were combined, the sensitivity was 86% (18/21; 95% CI 64-97%) and the specificity was 96% (1/23; 95% CI 78-100%). The fecal expression analysis of IFITM1 and IFITM2 mRNA by real-time RT-PCR for CRC screening exhibited high specificities, and the sensitivity was further improved by combining IFITM1 and IFITM2.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Pfister DG, Benson AB III and Somerfield MR: Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 350:2375–2382. 2004. View Article : Google Scholar : PubMed/NCBI
3	Mandel JS, Church TR, Bond JH, et al: The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 343:1603–1607. 2000. View Article : Google Scholar : PubMed/NCBI
4	Winawer S, Fletcher R, Rex D, et al: Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 124:544–560. 2003. View Article : Google Scholar : PubMed/NCBI
5	Smith A, Young GP, Cole SR and Bampton P: Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 107:2152–2159. 2006. View Article : Google Scholar
6	Levi Z, Rozen P, Hazazi R, et al: A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 146:244–255. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kronborg O, Fenger C, Olsen J, Jørgensen OD and Søndergaard O: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 348:1467–1471. 1996. View Article : Google Scholar : PubMed/NCBI
8	Hardcastle JD, Chamberlain JO, Robinson MH, et al: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 348:1472–1477. 1996. View Article : Google Scholar : PubMed/NCBI
9	Lieberman DA and Weiss DG: One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 345:555–560. 2001. View Article : Google Scholar : PubMed/NCBI
10	Sung JJ, Chan FK, Leung WK, et al: Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology. 124:608–614. 2003. View Article : Google Scholar : PubMed/NCBI
11	Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA and Ross ME: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 351:2704–2714. 2004. View Article : Google Scholar : PubMed/NCBI
12	Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T and Shiratori Y: A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 129:422–428. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ahlquist DA, Skoletsky JE, Boynton KA, et al: Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 119:1219–1227. 2000. View Article : Google Scholar : PubMed/NCBI
14	Dong SM, Traverso G, Johnson C, et al: Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 93:858–865. 2001. View Article : Google Scholar : PubMed/NCBI
15	Traverso G, Shuber A, Levin B, et al: Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med. 346:311–320. 2002. View Article : Google Scholar : PubMed/NCBI
16	Diehl F, Schmidt K, Durkee KH, et al: Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 135:489–498. 2008. View Article : Google Scholar : PubMed/NCBI
17	Lenhard K, Bommer GT, Asutay S, et al: Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 3:142–149. 2005. View Article : Google Scholar : PubMed/NCBI
18	Chen WD, Han ZJ, Skoletsky J, et al: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 97:1124–1132. 2005. View Article : Google Scholar : PubMed/NCBI
19	Zou H, Harrington J, Rego RL and Ahlquist DA: A novel method to capture methylated human DNA from stool: implications for colorectal cancer screening. Clin Chem. 53:1646–1651. 2007. View Article : Google Scholar : PubMed/NCBI
20	Müller HM, Oberwalder M, Fiegl H, et al: Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 363:1283–1285. 2004.PubMed/NCBI
21	Itzkowitz SH, Jandorf L, Brand R, et al: Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 5:111–117. 2007. View Article : Google Scholar : PubMed/NCBI
22	Leung WK, To KF, Man EP, et al: Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 102:1070–1076. 2007. View Article : Google Scholar : PubMed/NCBI
23	Boynton KA, Summerhayes IC, Ahlquist DA and Shuber AP: DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem. 49:1058–1065. 2003. View Article : Google Scholar : PubMed/NCBI
24	Zou H, Harrington JJ, Klatt KK and Ahlquist DA: A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 15:1115–1119. 2006. View Article : Google Scholar : PubMed/NCBI
25	Yamao T, Matsumura Y, Shimada Y, et al: Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology. 114:1196–1205. 1998. View Article : Google Scholar : PubMed/NCBI
26	Kanaoka S, Yoshida K, Miura N, Sugimura H and Kajimura M: Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology. 127:422–427. 2004. View Article : Google Scholar : PubMed/NCBI
27	Lagerholm S, Lagerholm S, Dutta S and Nair P: Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer. Scand J Gastroenterol. 40:1343–1350. 2005. View Article : Google Scholar : PubMed/NCBI
28	Yajima S, Ishii M, Matsushita H, et al: Expression profiling of fecal colonocytes for RNA-based screening of colorectal cancer. Int J Oncol. 31:1029–1037. 2007.PubMed/NCBI
29	Koga Y, Yasunaga M, Moriya Y, et al: Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci. 99:1977–1983. 2008.PubMed/NCBI
30	Takai T, Kanaoka S, Yoshida K, et al: Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assay as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 18:1888–1893. 2009. View Article : Google Scholar : PubMed/NCBI
31	Yu YJ, Majumdar AP, Nechvatal JM, et al: Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev. 17:455–458. 2008.PubMed/NCBI
32	Kitahara O, Furukawa Y, Tanaka T, et al: Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res. 61:3544–3549. 2001.
33	Andreu P, Colnot S, Godard C, et al: Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res. 66:1949–1955. 2006. View Article : Google Scholar : PubMed/NCBI
34	Akobeng AK: Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Pediatrica. 96:644–647. 2007. View Article : Google Scholar : PubMed/NCBI